Compare Bristol-Myers Squibb Co (BMY) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Dolby Laboratories, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $58.48 (market cap $116.30B), while Dolby Laboratories, Inc. trades at $49.68 (market cap $4.59B). The key difference: Bristol-Myers Squibb Co is far larger — about 25.3× Dolby Laboratories, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | DLB | |
|---|---|---|
Market Cap | $116.30B | $4.59B |
Sector | Health | Industrials |
52-Week High | $62.37 | $76.79 |
52-Week Low | $42.60 | $48.51 |
Enterprise Value | $152.24B | $4.04B |
Dividend Yield | 4.42% | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Dolby Laboratories (DLB) trades at $49.36, down 0.88% on the day, with a bearish technical outlook. The company maintains strong fundamentals, including a P/E of 19.59, a net income margin of 17.85%, and consistent earnings beats in recent quarters. Recent news highlights include its role in powering immersive audio for the FIFA World Cup 2026 coverage and recognition as a top supplier by General Motors.
The stock presents a value opportunity given its discount to the analyst consensus price target of $87.50, but faces near-term headwinds from bearish technical signals and cyclical end-market exposure. Upside potential hinges on continued licensing growth and execution, while risks include market sentiment and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
